Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Summit Therapeutics Inc.SMMT · Entity 3477 | Director | January 02, 2024 | January 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Summit Therapeutics Inc.
Report date January 02, 2024 · Filed January 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2034-01-02 | Direct | 35,000 |
Reported balance
After 2024-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-02 · Grant · Acquired 35,000 · Balance 35,000 F2: Not applicable. F1: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.64 · Expires 2034-01-02 | Direct | 87,575 |
Reported balance
After 2024-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-02 · Grant · Acquired 52,575 · Balance 87,575 F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $69,400. F3: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date.
F2: Not applicable.
F3: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date.
F4: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $69,400.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 4, 2024 21:22 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 52,575 | $1.32 Strike: $2.64 | $69,399.00 |
DisclosureSEC source: 0001599298-24-000010 · wk-form4_1704403313.xml · derivative · entry 2 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,575 Underlying: Common Stock · 52,575 shares Expires 2034-01-02 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $69,400. F3 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 21:22 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $2.64 | Not disclosed |
DisclosureSEC source: 0001599298-24-000010 · wk-form4_1704403313.xml · derivative · entry 1 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2034-01-02 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 2, 2024. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-salaried director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 40,500 | $1.67 Strike: $5.00 | $67,635.00 |
DisclosureSEC source: 0001599298-23-000006 · wf-form4_167295328081339.xml · derivative · entry 2 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,500 Underlying: Common Stock · 40,500 shares Expires 2033-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $67,500. F3 · derivative.exercise_date: The option was issued on January 3, 2023. The shares underlying the option shall vest in four equal quarterly installments on March 31, June 30, September 30 and December 31 following election, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 21:14 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 35,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001599298-23-000006 · wf-form4_167295328081339.xml · derivative · entry 1 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2023. The shares underlying the option shall vest in four equal annual installments on March 31, June 30, September 30 and December 31 of the year of grant, subject to the director remaining as a non-employee director on each such vesting date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:05 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 47,872 | $1.13 Strike: $2.82 | $54,095.36 |
DisclosureSEC source: 0001599298-22-000007 · wf-form4_164141670774490.xml · derivative · entry 2 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,872 Underlying: Common Stock · 47,872 shares Expires 2032-01-03 F4 · price: The option was issued to the reporting person pursuant to the issuer's Director Retainer Option Election Plan in lieu of retainer fees of $54,000. F3 · derivative.exercise_date: The option was issued on January 3, 2022. The shares underlying the option are scheduled to vest in four equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:05 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $2.82 | Not disclosed |
DisclosureSEC source: 0001599298-22-000007 · wf-form4_164141670774490.xml · derivative · entry 1 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-01-03 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on January 3, 2022. The shares underlying the option are scheduled to vest in equal quarterly installments, on March 31, 2022, June 30, 2022, September 30, 2022, and December 31, 2022. Read SEC document |
| February 19, 2021 Filed Feb 23, 2021 22:55 UTC | Summit Therapeutics Inc. SMMT · Entity 3477 | GrantStock Option (right to buy) · Derivative | 25,000 | Not disclosed Strike: $7.33 | Not disclosed |
DisclosureSEC source: 0000921895-21-000542 · form412566uja_02232021.xml · derivative · entry 1 Mahatme Ujwala · CIK 0001823894 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,340 Underlying: Common Stock · 25,000 shares Expires 2031-02-19 F2 · price: Not applicable. F1 · derivative.exercise_date: The option was granted on February 19, 2021. The shares underlying the option are scheduled to vest in full on December 31, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.